Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtriCure, Inc. - Common Stock (NQ:ATRC)

36.30 -0.15 (-0.40%)
Streaming Delayed Price Updated: 10:48 AM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
AtriCure to Announce First Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
Analyst Ratings for AtriCure
 
Via Benzinga
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
Earnings Outlook For AtriCure
 
Via Benzinga
AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
From AtriCure, Inc.
Via Business Wire
5 Analysts Have This to Say About AtriCure
Within the last quarter, AtriCure (NASDAQ:ATRC) has observed the following analyst ratings: 
Via Benzinga
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From AtriCure, Inc.
Via Business Wire
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award
From AtriCure, Inc.
Via Business Wire
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Third Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Third Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure: Q2 Earnings Insights
AtriCure (NASDAQ:ATRC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by... 
Via Benzinga
AtriCure Reports Second Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate at Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
5 Analysts Have This to Say About AtriCure
Over the past 3 months, 5 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AtriCure to Announce Second Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
Analyst Ratings for AtriCure
Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
From AtriCure, Inc.
Via Business Wire
AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
From AtriCure, Inc.
Via Business Wire
AtriCure's Q1 EPS Miss Estimates, Needham Lowers Price Target
Needham lowered AtriCure Inc's (NASDAQ: ATRC) price target to $67 from $79 due to peer multiple compression, with the Buy rating unchanged. 
Via Benzinga
4 Analysts Have This to Say About AtriCure
Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AtriCure: Q1 Earnings Insights
AtriCure (NASDAQ:ATRC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.